What's Happening?
TG Therapeutics, Inc. has reported a robust financial performance for the second quarter of 2026, with total global revenue reaching $240.3 million, surpassing management's guidance. The company's U.S. BRIUMVI revenue increased by 64% year-over-year,
driven by record patient starts and expanded physician adoption. The company has raised its full-year U.S. revenue guidance to between $890 million and $905 million, reflecting strong first-half performance and growing physician confidence in the brand. Additionally, TG Therapeutics is advancing its subcutaneous BRIUMVI formulation, with top-line Phase 3 results expected between late 2026 and early 2027. The company is also expanding its B-cell depletion platform into new autoimmune indications and developing alternative delivery methods to capture segments of the multiple sclerosis market previously inaccessible to intravenous therapies.
Why It's Important?
The financial success and strategic advancements of TG Therapeutics highlight the company's growing influence in the pharmaceutical industry, particularly in the treatment of multiple sclerosis. The increased revenue guidance and strong market performance indicate a solid foundation for future growth. The development of a subcutaneous formulation of BRIUMVI could significantly expand the company's market reach, allowing it to compete in the self-administered therapy segment. This expansion is crucial as it could potentially double the addressable market for BRIUMVI. Furthermore, the company's focus on innovation and expansion into new autoimmune indications demonstrates its commitment to long-term growth and value creation for shareholders.
What's Next?
TG Therapeutics plans to continue its strategic focus on expanding the BRIUMVI franchise. The company is preparing for the potential launch of its subcutaneous BRIUMVI formulation, which could significantly enhance its market position. Additionally, TG Therapeutics is set to launch an omnichannel direct-to-consumer campaign in the second half of 2026 to increase patient awareness. The company is also exploring business development opportunities to complement its existing autoimmune portfolio. As TG Therapeutics continues to innovate and expand its product offerings, it is well-positioned to capture a larger share of the multiple sclerosis market and drive long-term growth.
